Segment and Enterprise Wide Disclosures

12 Months Ended

Mar. 31, 2017

Segment Reporting [Abstract]

Segment and Enterprise Wide Disclosures

Note 13. Segment and Enterprise Wide Disclosures

The Company operates in one business segment—the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results. International sales (sales outside the U.S. and primarily in Europe) accounted for 9%, 8% and 10% of total product revenue during the fiscal years ended March 31, 2017, 2016 and 2015, respectively. As of March 31, 2017 and 2016, most of the Company’s long-lived assets are located in the U.S. except for $23.2 million and $5.9 million at March 31, 2017 and 2016, respectively, which are located primarily in Germany. As described in Note 6 above, the Company acquired its European headquarters in Aachen, Germany in February 2017 for $12.6 million.